Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.78M | 65.63M | 54.95M | 104.44M | 23.49M |
| Total Depreciation and Amortization | 3.79M | 3.77M | 3.52M | 3.41M | 3.23M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.95M | 7.90M | 7.55M | 7.44M | 6.51M |
| Change in Net Operating Assets | -93.06M | -118.85M | -79.98M | -129.49M | -122.34M |
| Cash from Operations | -54.55M | -41.56M | -13.97M | -14.19M | -89.12M |
| Capital Expenditure | -3.46M | -3.16M | -3.50M | -4.31M | -4.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -45.70M | -24.64M | -58.62M | 21.38M | -67.02M |
| Cash from Investing | -49.16M | -27.80M | -62.12M | 17.07M | -71.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 103.12M | 102.98M | 102.26M | 102.63M | 1.71M |
| Repurchase of Common Stock | -11.00K | -11.00K | -11.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.11M | 102.96M | 102.25M | 102.63M | 1.71M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -599.00K | 33.61M | 26.17M | 105.51M | -159.21M |